Aneurysm Is Restricted by CD34<sup>+</sup> Cell‐Formed Fibrous Collars Through the PDGFRb‐PI3K Axis
Aortic aneurysm is a life-threatening disease caused by progressive dilation of the aorta and weakened aortic walls. Its pathogenesis involves an imbalance between connective tissue repair and degradation. CD34<sup>+</sup> cells comprise a heterogeneous population that exhibits stem cell and progenitor cell properties. However, the role of CD34<sup>+</sup> cells in abdominal aortic aneurysm (AAA) remains unclear. In this study, downregulated CD34 expression is observed in aneurysmal aortas from both patients and mouse models compared to that in non-dilated aortas. Furthermore, by combining Cd34-CreER<sup>T2</sup>;Rosa26-tdTomato;(Apoe<sup>-/-</sup>) lineage tracing, bone marrow transplantation, and single-cell sequencing, it is found that during AAA development, non-bone marrow CD34<sup>+</sup> cells are activated to transdifferentiate into Periostin<sup>+</sup> myofibroblasts, thereby contributing to the formation of fibrotic collars. Dual recombinase-based lineage tracing confirms the presence and involvement of CD34<sup>+</sup>/Periostin<sup>+</sup> myofibroblasts in fibrotic collar formation during AAA development. Functionally, selective depletion of systemic or non-bone marrow CD34<sup>+</sup> cells, as well as CD34<sup>+</sup>/Periostin<sup>+</sup> myofibroblasts, by diphtheria toxin significantly exacerbates AAA progression and increases disease mortality. Mechanistically, it is identified that the PDGF-PDGFRb-PI3K axis is indispensable for Periostin<sup>+</sup> myofibroblast generation from non-bone marrow CD34<sup>+</sup> cells in AAA, offering a new therapeutic target for patients with AAA at a high risk of rupture.
Authors
- Kai Chen (ORCID: https://orcid.org/0000-0002-4059-796X)
- Qingbo Xu (ORCID: https://orcid.org/0000-0002-6414-2273)
- Bohuan Zhang
- Honghua Ye (ORCID: https://orcid.org/0000-0002-5737-3209)
- Yanhua Hu (ORCID: https://orcid.org/0000-0002-8149-5636)
- Hong-Kun Zhang (ORCID: https://orcid.org/0000-0002-6367-2416)
- Xuhao Zhou (ORCID: https://orcid.org/0000-0002-7181-607X)
- Qingzhong Xiao (ORCID: https://orcid.org/0000-0001-9101-0498)
- Junning Cheng (ORCID: https://orcid.org/0000-0002-3813-6566)
- Simon Xu
- Mengjia Chen (ORCID: https://orcid.org/0000-0001-6719-5648)
- Tao Zhang (ORCID: https://orcid.org/0000-0003-2765-2802)
- Jiangfang Lian (ORCID: https://orcid.org/0009-0002-5038-2775)
- Xiaoping Yang (ORCID: https://orcid.org/0000-0002-8943-3755)
- Ting Wang (ORCID: https://orcid.org/0000-0003-3414-5446)
- Baoqi Yu (ORCID: https://orcid.org/0009-0005-5150-2507)
- Hong Wu
- Liujun Jiang
- Ting Chen (ORCID: https://orcid.org/0000-0002-9723-9020)
Institutions
- Ningbo University (CN)
- University of Liverpool (GB)
- Queen Mary University of London (GB)
- Capital Medical University (CN)
- Peking University (CN)
- Liverpool Heart and Chest Hospital (GB)
- Ningbo Medical Center Lihuili Hospital (CN)
- Peking University People's Hospital (CN)
- William Harvey Research Institute (GB)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/advs.202408996
- Citations
- 3
- Primary Topic
- Aortic aneurysm repair treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- British Heart Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province